Research Progress of Novel Immune Checkpoint Inhibitors in the Clinical Treatment of Malignant Tumors
10.3870/j.issn.1004-0781.2025.12.020
- VernacularTitle:新型免疫检查点抑制剂在恶性肿瘤临床治疗中的研究进展
- Author:
Mengqing CHEN
1
;
Jing CAI
1
Author Information
1. 华中科技大学同济医学院附属协和医院妇产科,武汉 430022
- Publication Type:Journal Article
- Keywords:
Novel immune checkpoint;
Immune checkpoint inhibitors;
Immunotherapy;
Malignant tumor
- From:
Herald of Medicine
2025;44(12):2010-2022
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has become a crucial component of cancer treatment,with immune checkpoint inhibitors(ICIs)playing a pivotal role.Although programmed cell death protein 1/programmed cell death ligand 1(PD-1/PD-L1)and cytotoxic T-lymphocyte associated antigen 4(CTLA-4)inhibitors have demonstrated significant efficacy in various cancers,their widespread application is still limited by challenges such as drug resistance and immune-related adverse events(irAEs).To address these limitations,researchers are actively exploring next-generation immune checkpoint molecules.In recent years,novel immune checkpoint molecules,including lymphocyte activation gene-3(LAG-3),T-cell immunoglobulin and mucin domain-3(TIM-3),and T-cell immunoreceptor with Ig and ITIM domains(TIGIT),have shown promising therapeutic potential in both preclinical and clinical studies.This article summarizes the fundamental characteristics and mechanisms of these novel immune checkpoints,with a focus on the research progress of their inhibitors in the treatment of malignant tumors,aiming to provide valuable insights for future clinical applications.
